Australia · Delayed Price · Currency is AUD Orthocell Statistics
Total Valuation
Orthocell has a market cap or net worth of AUD 208.27 million. The enterprise value is 164.42 million.
| Market Cap | 208.27M |
| Enterprise Value | 164.42M |
Important Dates
The last earnings date was Friday, May 22, 2026.
| Earnings Date | May 22, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Orthocell has 272.25 million shares outstanding. The number of shares has increased by 14.29% in one year.
| Current Share Class | 272.25M |
| Shares Outstanding | 272.25M |
| Shares Change (YoY) | +14.29% |
| Shares Change (QoQ) | +7.69% |
| Owned by Insiders (%) | 14.74% |
| Owned by Institutions (%) | 3.30% |
| Float | 229.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 22.32 |
| PB Ratio | 5.06 |
| P/TBV Ratio | 5.20 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -13.17 |
| EV / Sales | 17.62 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -13.47 |
Financial Position
The company has a current ratio of 9.17, with a Debt / Equity ratio of 0.01.
| Current Ratio | 9.17 |
| Quick Ratio | 8.84 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.04 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -41.06% and return on invested capital (ROIC) is -33.78%.
| Return on Equity (ROE) | -41.06% |
| Return on Assets (ROA) | -20.97% |
| Return on Invested Capital (ROIC) | -33.78% |
| Return on Capital Employed (ROCE) | -30.91% |
| Weighted Average Cost of Capital (WACC) | 3.90% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.19 |
| Inventory Turnover | 2.56 |
Taxes
| Income Tax | -3.19M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.04% in the last 52 weeks. The beta is -0.06, so Orthocell's price volatility has been lower than the market average.
| Beta (5Y) | -0.06 |
| 52-Week Price Change | -37.04% |
| 50-Day Moving Average | 0.83 |
| 200-Day Moving Average | 1.02 |
| Relative Strength Index (RSI) | 35.72 |
| Average Volume (20 Days) | 219,915 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Orthocell had revenue of AUD 9.33 million and -12.48 million in losses. Loss per share was -0.05.
| Revenue | 9.33M |
| Gross Profit | 5.95M |
| Operating Income | -16.75M |
| Pretax Income | -15.67M |
| Net Income | -12.48M |
| EBITDA | -16.45M |
| EBIT | -16.75M |
| Loss Per Share | -0.05 |
Balance Sheet
The company has 44.37 million in cash and 510,603 in debt, with a net cash position of 43.86 million or 0.16 per share.
| Cash & Cash Equivalents | 44.37M |
| Total Debt | 510,603 |
| Net Cash | 43.86M |
| Net Cash Per Share | 0.16 |
| Equity (Book Value) | 41.16M |
| Book Value Per Share | 0.15 |
| Working Capital | 45.83M |
Cash Flow
In the last 12 months, operating cash flow was -12.05 million and capital expenditures -159,092, giving a free cash flow of -12.21 million.
| Operating Cash Flow | -12.05M |
| Capital Expenditures | -159,092 |
| Depreciation & Amortization | 297,708 |
| Net Borrowing | -242,186 |
| Free Cash Flow | -12.21M |
| FCF Per Share | -0.04 |
Margins
Gross margin is 63.77%, with operating and profit margins of -179.48% and -133.78%.
| Gross Margin | 63.77% |
| Operating Margin | -179.48% |
| Pretax Margin | -167.91% |
| Profit Margin | -133.78% |
| EBITDA Margin | -176.29% |
| EBIT Margin | -179.48% |
| FCF Margin | n/a |
Dividends & Yields
Orthocell does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.29% |
| Shareholder Yield | -14.29% |
| Earnings Yield | -5.99% |
| FCF Yield | -5.86% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for Orthocell is 1.25, which is 63.40% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 1.25 |
| Price Target Difference | 63.40% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Orthocell has an Altman Z-Score of 8.52 and a Piotroski F-Score of 3.
| Altman Z-Score | 8.52 |
| Piotroski F-Score | 3 |